{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T18:07:12Z","timestamp":1792260432869,"version":"4.4.0"},"reference-count":66,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"F. Hoffmann-La Roche Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Fonds de la Recherche en Sante","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015569","name":"Canadian Consortium on Neurodegeneration in Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015569","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010785","name":"Canada First Research Excellence Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010785","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Healthy Brains for Healthy Lives initiative"},{"name":"HBHL"},{"DOI":"10.13039\/501100012264","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012264","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Blood-based biomarkers for Alzheimer\u2019s disease (AD) pathology have been investigated intensively as markers for AD-related neurodegeneration. Comorbid AD pathology is common in dementia with Lewy bodies (DLB). Accordingly, we hypothesized that plasma biomarkers associated with AD pathology might be useful to predict DLB in a cohort of idiopathic\/isolated REM sleep behaviour disorder (iRBD), an incipient synucleinopathy. The aim of this study was to determine whether plasma amyloid-\u03b2 and pTau181 biomarkers can predict DLB.<\/jats:p>\n                  <jats:p>This longitudinal single-centre (Canada) cohort study included 158 individuals with polysomnography-confirmed iRBD between September 2004 and October 2022, each providing blood plasma samples, who were then offered prospective follow-up. Plasma A\u03b240, A\u03b242 and pTau181 levels were measured using NeuroToolKit, a prototype assay panel of neurodegeneration (Roche Diagnostics International Ltd). The primary outcome was the association between plasma biomarkers at baseline and eventual development of DLB. Correlations between plasma markers and baseline cognitive tests were assessed.<\/jats:p>\n                  <jats:p>A total of 142 iRBD participants [109 male (77%); mean \u00b1 SD, 67.6 \u00b1 8.0 years of age] were included in the final analysis. On prospective follow-up (2.9 \u00b1 2.1 years after sampling), 32 individuals phenoconverted to a defined neurodegenerative syndrome (18 DLB, 13 Parkinson\u2019s disease and one multiple system atrophy). The combined phenoconvertor group had lower baseline plasma A\u03b242\/40 ratio compared with non-phenoconvertors (mean \u00b1 SD, 0.103 \u00b1 0.010 versus 0.114 \u00b1 0.012, P &amp;lt; 0.001) and higher pTau181 levels (0.993 \u00b1 0.354 versus 0.784 \u00b1 0.266\u2005pg\/ml, P = 0.008). When divided by phenoconversion subtype, significant differences were seen selectively in DLB convertors [A\u03b242\/40 = 0.101 \u00b1 0.010, difference \u22120.011, 95% confidence interval (\u22120.016; \u22120.005), P &amp;lt; 0.001; pTau181 = 1.144 \u00b1 0.326\u2005pg\/ml, difference 0.282\u2005pg\/ml, 95% confidence interval (0.146; 0.418), P &amp;lt; 0.001]. Cross-sectional analysis showed that plasma pTau181 (but not A\u03b242\/40) was correlated with cognitive tests across various domains.<\/jats:p>\n                  <jats:p>Our results indicate that plasma A\u03b242\/40 ratio and pTau181 can predict conversion to DLB in iRBD.<\/jats:p>","DOI":"10.1093\/brain\/awaf003","type":"journal-article","created":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T15:19:12Z","timestamp":1735831152000},"page":"2049-2059","source":"Crossref","is-referenced-by-count":31,"title":["Plasma pTau181 and amyloid markers predict conversion to dementia in idiopathic REM sleep behaviour disorder"],"prefix":"10.1093","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8497-2314","authenticated-orcid":false,"given":"Aline","family":"Delva","sequence":"first","affiliation":[{"name":"The Neuro (Montreal Neurological Institute-Hospital), McGill University , Montreal, QC H3A 2B4 ,","place":["Canada"]},{"name":"Department of Neurology and Neurosurgery, McGill University , Montreal, QC H3A 2B4 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00e9lie","family":"Pelletier","sequence":"additional","affiliation":[{"name":"Centre for Advanced Research in Sleep Medicine, H\u00f4pital du Sacr\u00e9-Coeur de Montr\u00e9al , Montreal, QC H4J 1C5 ,","place":["Canada"]},{"name":"Department of Neurology, Research Institute of McGill University Health Centre , Montreal, QC H4A 3J1 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Somerville","sequence":"additional","affiliation":[{"name":"The Neuro (Montreal Neurological Institute-Hospital), McGill University , Montreal, QC H3A 2B4 ,","place":["Canada"]},{"name":"Department of Human Genetics, McGill University , Montreal, QC H3A 2B4 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Montplaisir","sequence":"additional","affiliation":[{"name":"Centre for Advanced Research in Sleep Medicine, H\u00f4pital du Sacr\u00e9-Coeur de Montr\u00e9al , Montreal, QC H4J 1C5 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Gagnon","sequence":"additional","affiliation":[{"name":"Centre for Advanced Research in Sleep Medicine, H\u00f4pital du Sacr\u00e9-Coeur de Montr\u00e9al , Montreal, QC H4J 1C5 ,","place":["Canada"]},{"name":"Department of Psychology, Universit\u00e9 du Qu\u00e9bec \u00e0 Montr\u00e9al , Montreal, QC H2L 2C4 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwendlyn","family":"Kollmorgen","sequence":"additional","affiliation":[{"name":"Roche Diagnostics GmbH , Penzberg 82377 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Kam-Thong","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd , Basel 4052 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kustermann","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Neurosciences and Rare Diseases, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd , Basel 4052 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venissa","family":"Machado","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Neurosciences and Rare Diseases, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd , Basel 4052 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0332-234X","authenticated-orcid":false,"given":"Ziv","family":"Gan-Or","sequence":"additional","affiliation":[{"name":"The Neuro (Montreal Neurological Institute-Hospital), McGill University , Montreal, QC H3A 2B4 ,","place":["Canada"]},{"name":"Department of Neurology and Neurosurgery, McGill University , Montreal, QC H3A 2B4 ,","place":["Canada"]},{"name":"Department of Human Genetics, McGill University , Montreal, QC H3A 2B4 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald B","family":"Postuma","sequence":"additional","affiliation":[{"name":"The Neuro (Montreal Neurological Institute-Hospital), McGill University , Montreal, QC H3A 2B4 ,","place":["Canada"]},{"name":"Department of Neurology and Neurosurgery, McGill University , Montreal, QC H3A 2B4 ,","place":["Canada"]},{"name":"Centre for Advanced Research in Sleep Medicine, H\u00f4pital du Sacr\u00e9-Coeur de Montr\u00e9al , Montreal, QC H4J 1C5 ,","place":["Canada"]},{"name":"Department of Neurology, Research Institute of McGill University Health Centre , Montreal, QC H4A 3J1 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,6]]},"reference":[{"key":"2025060300223508100_awaf003-B1","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1001\/jamaneurol.2018.0629","article-title":"Prevalence and outcomes of amyloid positivity among persons without dementia in a longitudinal, population-based setting","volume":"75","author":"Roberts","year":"2018","journal-title":"JAMA Neurol"},{"key":"2025060300223508100_awaf003-B2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s13195-023-01314-6","article-title":"Biomarkers in Alzheimer\u2019s disease: Role in early and differential diagnosis and recognition of atypical variants","volume":"15","author":"Dubois","year":"2023","journal-title":"Alzheimers Res Ther"},{"key":"2025060300223508100_awaf003-B3","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1212\/WNL.0b013e31823ed0f0","article-title":"Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort","volume":"78","author":"Schoonenboom","year":"2012","journal-title":"Neurology"},{"key":"2025060300223508100_awaf003-B4","doi-asserted-by":"crossref","first-page":"e14408","DOI":"10.15252\/emmm.202114408","article-title":"Blood-based biomarkers for Alzheimer\u2019s disease","volume":"14","author":"Leuzy","year":"2022","journal-title":"EMBO Mol Med"},{"key":"2025060300223508100_awaf003-B5","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","article-title":"Plasma P-tau181 in Alzheimer\u2019s disease: Relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia","volume":"26","author":"Janelidze","year":"2020","journal-title":"Nat Med"},{"key":"2025060300223508100_awaf003-B6","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders","volume":"324","author":"Palmqvist","year":"2020","journal-title":"JAMA"},{"key":"2025060300223508100_awaf003-B7","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1474-4422(21)00214-3","article-title":"Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer\u2019s disease and frontotemporal lobar degeneration: A retrospective diagnostic performance study","volume":"20","author":"Thijssen","year":"2021","journal-title":"Lancet Neurol"},{"key":"2025060300223508100_awaf003-B8","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1038\/s41591-022-02074-w","article-title":"Differential roles of A\u03b242\/40, p-tau231 and p-tau217 for Alzheimer\u2019s trial selection and disease monitoring","volume":"28","author":"Ashton","year":"2022","journal-title":"Nat Med"},{"key":"2025060300223508100_awaf003-B9","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","article-title":"Plasma phospho-tau181 increases with Alzheimer\u2019s disease clinical severity and is associated with tau- and amyloid-positron emission tomography","volume":"14","author":"Mielke","year":"2018","journal-title":"Alzheimers Dement"},{"key":"2025060300223508100_awaf003-B10","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.neurobiolaging.2020.01.007","article-title":"Plasma amyloid is associated with the rate of cognitive decline in cognitively normal elderly: The SCIENCe project","volume":"89","author":"Verberk","year":"2020","journal-title":"Neurobiol Aging"},{"key":"2025060300223508100_awaf003-B11","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1002\/alz.12751","article-title":"An accurate fully automated panel of plasma biomarkers for Alzheimer\u2019s disease","volume":"19","author":"Palmqvist","year":"2023","journal-title":"Alzheimers Dement"},{"key":"2025060300223508100_awaf003-B12","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1038\/s41467-021-23746-0","article-title":"Plasma biomarkers of Alzheimer\u2019s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations","volume":"12","author":"Cullen","year":"2021","journal-title":"Nat Commun"},{"key":"2025060300223508100_awaf003-B13","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.parkreldis.2014.02.012","article-title":"Concomitant pathologies among a spectrum of parkinsonian disorders","volume":"20","author":"Dugger","year":"2014","journal-title":"Parkinsonism Relat Disord"},{"key":"2025060300223508100_awaf003-B14","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/bpa.12182","article-title":"Regional multiple pathology scores are associated with cognitive decline in Lewy body dementias","volume":"25","author":"Howlett","year":"2015","journal-title":"Brain Pathol"},{"key":"2025060300223508100_awaf003-B15","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/alz.13398","article-title":"ATN cerebrospinal fluid biomarkers in dementia with Lewy bodies: Initial results from the United States Dementia with Lewy Bodies Consortium","volume":"20","author":"Jain","year":"2024","journal-title":"Alzheimers Dement"},{"key":"2025060300223508100_awaf003-B16","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13195-019-0537-5","article-title":"Amyloid-\u03b2 peptides in cerebrospinal fluid of patients with dementia with Lewy bodies","volume":"11","author":"van Steenoven","year":"2019","journal-title":"Alzheimers Res Ther"},{"key":"2025060300223508100_awaf003-B17","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1136\/jnnp-2021-327788","article-title":"Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer\u2019s disease, frontotemporal dementia and progressive supranuclear palsy","volume":"93","author":"Chouliaras","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2025060300223508100_awaf003-B18","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1001\/jamaneurol.2021.4222","article-title":"Association of plasma p-tau181 and p-tau231 concentrations with cognitive decline in patients with probable dementia with Lewy bodies","volume":"79","author":"Gonzalez","year":"2022","journal-title":"JAMA Neurol"},{"key":"2025060300223508100_awaf003-B19","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1002\/alz.13653","article-title":"Plasma biomarkers of Alzheimer\u2019s disease in the continuum of dementia with Lewy bodies","volume":"20","author":"Diaz-Galvan","year":"2024","journal-title":"Alzheimers Dement"},{"key":"2025060300223508100_awaf003-B20","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/mds.28994","article-title":"A longitudinal study of plasma pTau181 in mild cognitive impairment with Lewy bodies and Alzheimer\u2019s disease","volume":"37","author":"Thomas","year":"2022","journal-title":"Mov Disord"},{"key":"2025060300223508100_awaf003-B21","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s13195-024-01502-y","article-title":"Plasma biomarkers of amyloid, tau, axonal, and neuroinflammation pathologies in dementia with Lewy bodies","volume":"16","author":"Vrillon","year":"2024","journal-title":"Alzheimers Res Ther"},{"key":"2025060300223508100_awaf003-B22","doi-asserted-by":"crossref","first-page":"e209418","DOI":"10.1212\/WNL.0000000000209418","article-title":"Association of plasma amyloid, P-tau, GFAP, and NfL with CSF, clinical, and cognitive features in patients with dementia with Lewy bodies","volume":"102","author":"Bolsewig","year":"2024","journal-title":"Neurology"},{"key":"2025060300223508100_awaf003-B23","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1136\/jnnp-2022-330709","article-title":"Elevated plasma p-tau181 levels unrelated to Alzheimer\u2019s disease pathology in amyotrophic lateral sclerosis","volume":"94","author":"Vacchiano","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2025060300223508100_awaf003-B24","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/ana.26462","article-title":"Elevated plasma phosphorylated tau 181 in amyotrophic lateral sclerosis","volume":"92","author":"Cousins","year":"2022","journal-title":"Ann Neurol"},{"key":"2025060300223508100_awaf003-B25","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1093\/brain\/awz030","article-title":"Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: A multicentre study","volume":"142","author":"Postuma","year":"2019","journal-title":"Brain"},{"key":"2025060300223508100_awaf003-B26","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/alz.13386","article-title":"Prodromal dementia with Lewy bodies in REM sleep behavior disorder: A multicenter study","volume":"20","author":"Joza","year":"2024","journal-title":"Alzheimers Dement"},{"key":"2025060300223508100_awaf003-B27","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1093\/brain\/awz111","article-title":"Evolution of prodromal Parkinson\u2019s disease and dementia with Lewy bodies: A prospective study","volume":"142","author":"Fereshtehnejad","year":"2019","journal-title":"Brain"},{"key":"2025060300223508100_awaf003-B28","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S1474-4422(23)00109-6","article-title":"Assessment of heterogeneity among participants in the Parkinson\u2019s Progression Markers Initiative cohort using \u03b1-synuclein seed amplification: A cross-sectional study","volume":"22","author":"Siderowf","year":"2023","journal-title":"Lancet Neurol"},{"key":"2025060300223508100_awaf003-B29","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1093\/brain\/awad072","article-title":"Progression of clinical markers in prodromal Parkinson\u2019s disease and dementia with Lewy bodies: A multicentre study","volume":"146","author":"Joza","year":"2023","journal-title":"Brain"},{"key":"2025060300223508100_awaf003-B30","doi-asserted-by":"crossref","first-page":"105557","DOI":"10.1016\/j.nbd.2021.105557","article-title":"Neuropathological evidence of body-first vs. brain-first Lewy body disease","volume":"161","author":"Borghammer","year":"2021","journal-title":"Neurobiol Dis"},{"key":"2025060300223508100_awaf003-B31","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/mds.26605","article-title":"Neuropathological basis of nonmotor manifestations of Parkinson\u2019s disease","volume":"31","author":"Adler","year":"2016","journal-title":"Mov Disord"},{"issue":"24 Pt A","key":"2025060300223508100_awaf003-B32","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1016\/j.febslet.2015.10.021","article-title":"Understanding the susceptibility of dopamine neurons to mitochondrial stressors in Parkinson\u2019s disease","volume":"589","author":"Haddad","year":"2015","journal-title":"FEBS Lett"},{"key":"2025060300223508100_awaf003-B33","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1038\/s41591-023-02450-0","article-title":"Cognitive effects of Lewy body pathology in clinically unimpaired individuals","volume":"29","author":"Palmqvist","year":"2023","journal-title":"Nat Med"},{"key":"2025060300223508100_awaf003-B34","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1038\/s41591-023-02449-7","article-title":"Clinical effects of Lewy body pathology in cognitively impaired individuals","volume":"29","author":"Quadalti","year":"2023","journal-title":"Nat Med"},{"key":"2025060300223508100_awaf003-B35","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimers Dement"},{"key":"2025060300223508100_awaf003-B36","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41380-020-0721-9","article-title":"Biomarkers for Alzheimer\u2019s disease\u2014preparing for a new era of disease-modifying therapies","volume":"26","author":"Zetterberg","year":"2021","journal-title":"Mol Psychiatry"},{"key":"2025060300223508100_awaf003-B37","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1002\/mds.23257","article-title":"Polysomnographic diagnosis of idiopathic REM sleep behavior disorder","volume":"25","author":"Montplaisir","year":"2010","journal-title":"Mov Disord"},{"key":"2025060300223508100_awaf003-B38","volume-title":"International classification of sleep disorders\u20143","author":"American Academy of Medicine","year":"2014"},{"key":"2025060300223508100_awaf003-B39","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson\u2019s disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov Disord"},{"key":"2025060300223508100_awaf003-B40","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/mds.29005","article-title":"The Movement Disorder Society criteria for the diagnosis of multiple system atrophy","volume":"37","author":"Wenning","year":"2022","journal-title":"Mov Disord"},{"key":"2025060300223508100_awaf003-B41","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB consortium","volume":"89","author":"McKeith","year":"2017","journal-title":"Neurology"},{"key":"2025060300223508100_awaf003-B42","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1212\/WNL.0000000000001364","article-title":"Parkinson risk in idiopathic REM sleep behavior disorder: Preparing for neuroprotective trials","volume":"84","author":"Postuma","year":"2015","journal-title":"Neurology"},{"key":"2025060300223508100_awaf003-B43","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","article-title":"The Montreal cognitive assessment, MoCA: A brief screening tool for mild cognitive impairment","volume":"53","author":"Nasreddine","year":"2005","journal-title":"J Am Geriatr Soc"},{"key":"2025060300223508100_awaf003-B44","volume-title":"Army individual test battery: Manual of directions and scoring","author":"APA PsycTests","year":"1944"},{"key":"2025060300223508100_awaf003-B45","volume-title":"WAIS-III: Administration and scoring manual: Wechsler adult intelligence scale","author":"Wechsler","year":"1997"},{"key":"2025060300223508100_awaf003-B46","volume-title":"Delis-Kaplan executive function system: Technical manual","author":"Delis","year":"2001"},{"key":"2025060300223508100_awaf003-B47","volume-title":"Contributions to neuropsychological assessment","author":"Benton","year":"1983"},{"key":"2025060300223508100_awaf003-B48","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1076\/jcen.20.2.194.1173","article-title":"Mayo\u2019s older Americans normative studies: Category fluency norms","volume":"20","author":"Lucas","year":"1998","journal-title":"J Clin Exp Neuropsychol"},{"key":"2025060300223508100_awaf003-B49","volume-title":"L\u2019examen clinique en psychologie","author":"Rey","year":"1964"},{"key":"2025060300223508100_awaf003-B50","first-page":"286","article-title":"L\u2019examen psychologique dans les cas d\u2019encephalopathie traumatique","volume":"28","author":"Rey","year":"1941","journal-title":"Arch Psychol"},{"key":"2025060300223508100_awaf003-B51","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1364\/JOSA.33.000568","article-title":"The Farnsworth\u2013Munsell 100 hue test and dichotomous tests for colour vision","volume":"33","author":"Farnsworth","year":"1943","journal-title":"J Opt Soc Am"},{"key":"2025060300223508100_awaf003-B52","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/ana.21680","article-title":"Mild cognitive impairment in rapid eye movement sleep behavior disorder and Parkinson\u2019s disease","volume":"66","author":"Gagnon","year":"2009","journal-title":"Ann Neurol"},{"key":"2025060300223508100_awaf003-B53","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1086\/519795","article-title":"PLINK: A tool set for whole-genome association and population-based linkage analyses","volume":"81","author":"Purcell","year":"2007","journal-title":"Am J Hum Genet"},{"key":"2025060300223508100_awaf003-B54","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41586-021-03205-y","article-title":"Sequencing of 53,831 diverse genomes from the NHLBI TOPMed program","volume":"590","author":"Taliun","year":"2021","journal-title":"Nature"},{"key":"2025060300223508100_awaf003-B55","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1038\/ng.3656","article-title":"Next-generation genotype imputation service and methods","volume":"48","author":"Das","year":"2016","journal-title":"Nat Genet"},{"key":"2025060300223508100_awaf003-B56","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","article-title":"Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology","volume":"81","author":"Ashton","year":"2024","journal-title":"JAMA Neurol"},{"key":"2025060300223508100_awaf003-B57","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/jnnp-2022-330619","article-title":"Plasma biomarkers for Alzheimer\u2019s disease: A field-test in a memory clinic","volume":"94","author":"Altomare","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2025060300223508100_awaf003-B58","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.parkreldis.2022.07.008","article-title":"The relationship between plasma biomarkers and amyloid PET in dementia with Lewy bodies","volume":"101","author":"Donaghy","year":"2022","journal-title":"Parkinsonism Relat Disord"},{"key":"2025060300223508100_awaf003-B59","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/ana.25239","article-title":"How does dementia with Lewy bodies start? Prodromal cognitive changes in REM sleep behavior disorder","volume":"83","author":"Genier Marchand","year":"2018","journal-title":"Ann Neurol"},{"key":"2025060300223508100_awaf003-B60","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","article-title":"A\/T\/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers","volume":"87","author":"Jack","year":"2016","journal-title":"Neurology"},{"key":"2025060300223508100_awaf003-B61","doi-asserted-by":"crossref","first-page":"e1182","DOI":"10.1212\/WNL.0000000000006212","article-title":"APOE \u03b54 is associated with severity of Lewy body pathology independent of Alzheimer pathology","volume":"91","author":"Dickson","year":"2018","journal-title":"Neurology"},{"key":"2025060300223508100_awaf003-B62","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/alz.12049","article-title":"Risk factors for earlier dementia onset in autopsy-confirmed Alzheimer\u2019s disease, mixed Alzheimer\u2019s with Lewy bodies, and pure Lewy body disease","volume":"16","author":"Schaffert","year":"2020","journal-title":"Alzheimers Dement"},{"key":"2025060300223508100_awaf003-B63","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1007\/s11357-023-00883-6","article-title":"Involvement of ApoE4 in dementia with Lewy bodies in the prodromal and demented stages: Evaluation of the Strasbourg cohort","volume":"46","author":"Bousiges","year":"2024","journal-title":"Geroscience"},{"key":"2025060300223508100_awaf003-B64","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.sleep.2012.10.015","article-title":"Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder","volume":"14","author":"Boeve","year":"2013","journal-title":"Sleep Med"},{"key":"2025060300223508100_awaf003-B65","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/ana.25687","article-title":"Fine-mapping of SNCA in rapid eye movement sleep behavior disorder and overt synucleinopathies","volume":"87","author":"Krohn","year":"2020","journal-title":"Ann Neurol"},{"key":"2025060300223508100_awaf003-B66","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s00401-020-02157-3","article-title":"The structural differences between patient-derived \u03b1-synuclein strains dictate characteristics of Parkinson\u2019s disease, multiple system atrophy and dementia with Lewy bodies","volume":"139","author":"Van der Perren","year":"2020","journal-title":"Acta Neuropathol"}],"container-title":["Brain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/brain\/advance-article-pdf\/doi\/10.1093\/brain\/awaf003\/61356754\/awaf003.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/148\/6\/2049\/61356754\/awaf003.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/148\/6\/2049\/61356754\/awaf003.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:23:01Z","timestamp":1748910181000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/brain\/article\/148\/6\/2049\/7943632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,6]]},"references-count":66,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,1,6]]},"published-print":{"date-parts":[[2025,6,3]]}},"URL":"https:\/\/doi.org\/10.1093\/brain\/awaf003","relation":{},"ISSN":["0006-8950","1460-2156"],"issn-type":[{"value":"0006-8950","type":"print"},{"value":"1460-2156","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,1,6]]}}}